Fiserv earnings missed by $0.61, revenue fell short of estimates
CRISPR Therapeutics AG (NASDAQ:CRSP) Chief Executive Officer Samarth Kulkarni sold 50,895 shares of the company’s common stock on October 17, 2025, at a price of $67.91, totaling $3,456,279. The sale comes as the $6.7 billion biotech company’s stock trades near its 52-week high of $78.48, having surged over 83% in the past six months. According to InvestingPro analysis, the stock appears slightly overvalued at current levels.
According to a Form 4 filing with the Securities and Exchange Commission, Kulkarni also exercised options to acquire 100,000 common shares on October 16, 2025.
Following the sale, Kulkarni directly owns 254,201 shares of CRISPR Therapeutics AG. Additionally, he indirectly owns 85,662 shares through The Kulkarni 2023 GRAT.
In other recent news, CRISPR Therapeutics has filed a prospectus supplement with the U.S. Securities and Exchange Commission to offer and sell additional common shares worth up to $600 million. The shares will be sold through Jefferies LLC under an existing Open Market Sale Agreement, with issuance at the company’s discretion. Meanwhile, Citizens has reiterated a Market Outperform rating for CRISPR Therapeutics, maintaining a price target of $86.00, following discussions about the company’s SyNTase Editor technology. BMO Capital also reiterated an Outperform rating with a $75.00 price target, noting the potential in the thrombosis market through a partnership with Sirius on FXI siRNA SRSD107. H.C. Wainwright has maintained its Buy rating with an $80.00 price target, emphasizing the untapped potential of SRSD107 in the anticoagulation market. Additionally, CRISPR Therapeutics presented promising preclinical data for its alpha-1 antitrypsin deficiency treatment candidate at the European Society of Gene and Cell Therapy Annual Congress. The investigational therapy, CTX460, showed significant efficacy in disease models, achieving over 90% mRNA correction and more than 99% serum M-AAT:Z-AAT ratio following a single dose. These developments highlight CRISPR Therapeutics’ ongoing advancements in gene editing and therapeutic applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.